- Home
- GNL vs IBRX Comparison
GNL vs IBRX Comparison
Compare GNL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNL
- IBRX
- Stock Information
- Founded
- GNL 2011
- IBRX 2014
- Country
- GNL United States
- IBRX United States
- Employees
- GNL N/A
- IBRX N/A
- Industry
- GNL Real Estate Investment Trusts
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNL Real Estate
- IBRX Health Care
- Exchange
- GNL Nasdaq
- IBRX Nasdaq
- Market Cap
- GNL 1.6B
- IBRX 1.9B
- IPO Year
- GNL N/A
- IBRX N/A
- Fundamental
- Price
- GNL $7.37
- IBRX $3.22
- Analyst Decision
- GNL Buy
- IBRX Strong Buy
- Analyst Count
- GNL 5
- IBRX 3
- Target Price
- GNL $9.50
- IBRX $13.58
- AVG Volume (30 Days)
- GNL 1.7M
- IBRX 6.3M
- Earning Date
- GNL 02-25-2025
- IBRX 11-12-2024
- Dividend Yield
- GNL 14.99%
- IBRX N/A
- EPS Growth
- GNL N/A
- IBRX N/A
- EPS
- GNL N/A
- IBRX N/A
- Revenue
- GNL $812,621,000.00
- IBRX $7,332,000.00
- Revenue This Year
- GNL N/A
- IBRX $2,515.60
- Revenue Next Year
- GNL N/A
- IBRX $766.19
- P/E Ratio
- GNL N/A
- IBRX N/A
- Revenue Growth
- GNL 102.00
- IBRX 1218.71
- 52 Week Low
- GNL $6.52
- IBRX $2.28
- 52 Week High
- GNL $9.11
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- GNL 53.77
- IBRX 54.04
- Support Level
- GNL $7.11
- IBRX $2.28
- Resistance Level
- GNL $7.29
- IBRX $3.30
- Average True Range (ATR)
- GNL 0.17
- IBRX 0.26
- MACD
- GNL 0.01
- IBRX 0.13
- Stochastic Oscillator
- GNL 72.35
- IBRX 92.16
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail ; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.